Janus Henderson Group PLC Buys Shares of 1,096,302 Septerna, Inc. (NASDAQ:SEPN)

Janus Henderson Group PLC bought a new position in shares of Septerna, Inc. (NASDAQ:SEPN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 1,096,302 shares of the company's stock, valued at approximately $25,111,000. Janus Henderson Group PLC owned approximately 2.47% of Septerna as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. RA Capital Management L.P. bought a new position in Septerna in the fourth quarter valued at $160,205,000. TRV GP V LLC purchased a new position in shares of Septerna in the 4th quarter worth about $142,337,000. TRV GP VI LLC purchased a new position in shares of Septerna in the 4th quarter worth about $72,191,000. Samsara BioCapital LLC bought a new position in shares of Septerna during the 4th quarter valued at about $63,399,000. Finally, Driehaus Capital Management LLC purchased a new position in shares of Septerna during the 4th quarter valued at about $59,301,000.

Septerna Stock Performance

SEPN stock traded up $0.13 during midday trading on Monday, hitting $9.97. The company had a trading volume of 1,070,933 shares, compared to its average volume of 715,670. Septerna, Inc. has a 52 week low of $4.17 and a 52 week high of $28.99. The stock's 50 day moving average price is $6.43 and its 200 day moving average price is $14.17.

Septerna (NASDAQ:SEPN - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). The company had revenue of $0.22 million for the quarter. Analysts expect that Septerna, Inc. will post -7.11 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on SEPN shares. Wells Fargo & Company upped their price objective on shares of Septerna from $11.00 to $18.00 and gave the company an "equal weight" rating in a research note on Friday. Cantor Fitzgerald raised their price objective on Septerna from $20.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday.

Insider Transactions at Septerna

In other Septerna news, CFO Gil M. Labrucherie bought 10,500 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The stock was bought at an average price of $5.51 per share, for a total transaction of $57,855.00. Following the completion of the acquisition, the chief financial officer now directly owns 10,500 shares in the company, valued at $57,855. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Alan Ezekowitz purchased 41,355 shares of the company's stock in a transaction that occurred on Thursday, March 6th. The stock was acquired at an average cost of $6.00 per share, with a total value of $248,130.00. Following the purchase, the director now directly owns 104,101 shares of the company's stock, valued at $624,606. This trade represents a 65.91% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 74,346 shares of company stock worth $439,670. Company insiders own 4.30% of the company's stock.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.